All Tax inversion articles
-
BusinessUS government sued over merger crackdown
Business groups challenge Obama’s steps to limit tax inversions
-
BusinessUS tax rules force fertiliser merger to fall flat
CF Industries’ $8bn merger plan to relocate from US to Europe scuppered by regulatory changes
-
BusinessUS treasury rules scupper Pfizer–Allergan merger
Government aims to crack down on corporate tax avoidance through ‘inversion’ deals
-
BusinessPfizer and Allergan agree mega-merger
$160 billion deal allows Pfizer to escape US tax system by re-homing in Ireland
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Hospira buyout is a shot in the arm for Pfizer’s biosimilars
$17bn deal, intended to bolster sterile injectable and biologics capabilities, will be financed with existing cash and new debt
-
-
BusinessActavis rescues Allergan with $66 billion deal
Deal ends takeover fight with Valeant – but Actavis must still be ‘fairly ruthless’ to justify the high price
-
Business
AbbVie backs out of Shire deal
Treasury rule changes make inversion ‘too uncertain’ and remove financial benefits
-
Business
US tax changes ripple into merger deals
Efforts to curb tax-avoiding ‘inversion’ deals will slow, but not stop, the wave
-
BusinessPharma firms rush to escape US tax shackles
AbbVie–Shire and Mylan–Abbott mergers both allow US firms to escape to lower-tax European countries
-
Business
Time called on Pfizer–AstraZeneca deal
Pfizer could make a fresh approach after six months under City takeover rules
-
Business
AstraZeneca refuses Pfizer’s ‘final’ offer
Pfizer pledges not to make hostile bid direct to shareholders